Future trends in PV outsourcing, automation and shared service models Future Trends in Pharmacovigilance Outsourcing, Automation, and Shared Service Models Introduction to Pharmacovigilance Outsourcing Pharmacovigilance (PV) is essential in monitoring the safety of medicinal products, ensuring their acceptable benefit-risk balance. In recent years, the landscape of pharmacovigilance has seen significant shifts, particularly in outsourcing practices, automation technologies, and shared service models. Understanding these trends is paramount for pharmaceutical professionals, clinical operations, regulatory affairs, and medical affairs roles seeking to maintain compliance with US FDA regulations while optimizing resources. In this tutorial, we will delve into the core areas of pharmacovigilance…

Building a Hybrid Pharmacovigilance Organisation with In-House and Outsourced Activities Introduction to Hybrid Pharmacovigilance Models As the demand for comprehensive pharmacovigilance (PV) programs grows, pharmaceutical companies are increasingly adopting hybrid PV models that leverage both in-house resources and outsourced activities. This approach allows for greater flexibility and efficiency in managing the complex landscape of drug safety monitoring. Understanding the operational and regulatory frameworks that govern these hybrid models is essential for compliance and effective vendor oversight. This tutorial outlines the key steps to effectively build a hybrid PV organization, focusing on pharmacovigilance agreements, vendor oversight, and outsourcing models. We will…

Regulatory Inspection Focus on PV Agreements and Vendor Oversight Understanding Regulatory Inspections: Focus on Pharmacovigilance Agreements and Vendor Oversight The pharmaceutical industry faces an increasing level of scrutiny from regulatory authorities to ensure robust safety monitoring throughout the product lifecycle. As the landscape of pharmacovigilance (PV) evolves, especially with outsourcing and the utilization of various vendors, regulatory inspections increasingly focus on the management and oversight of pharmacovigilance agreements and associated vendor oversight practices. This article serves as a comprehensive guide for pharma professionals, clinical operations, and regulatory affairs experts to navigate the intricate requirements surrounding PV agreements, vendor audits, and…

Onboarding Checklists for New PV Vendors and Service Partners In the ever-evolving landscape of pharmacovigilance (PV), the onboarding process for new vendors and service partners is crucial to ensure compliance with regulatory requirements and maintain the quality of safety data management. This comprehensive guide provides a step-by-step approach to effectively onboard new PV vendors while ensuring adherence to applicable regulations, especially focusing on pharmacovigilance agreements, vendor oversight, outsourcing models, and more. Understanding the Regulatory Framework Before onboarding new PV vendors, it is essential to establish a firm understanding of the regulatory requirements that govern pharmacovigilance activities in various regions, particularly…

Integrating vendor performance into PV risk management and audit plans Integrating Vendor Performance into Pharmacovigilance Risk Management and Audit Plans Introduction to Pharmacovigilance and Vendor Oversight Pharmacovigilance (PV) is an essential component of drug safety, ensuring the continuous monitoring of adverse effects and enhancing the safety profile of pharmaceutical products throughout their lifecycle. In a rapidly evolving pharmaceutical landscape, the integration of vendor performance into PV risk management and audit plans is crucial. As outsourcing models become the norm, organizations must establish robust pharmacovigilance agreements (PVAs) to ensure compliance with regulatory requirements and safeguard patient safety. Organizations often rely on…

Traceability and Product Identification Issues in Biosimilar PV Systems Traceability and Product Identification Issues in Biosimilar Pharmacovigilance Systems As regulatory scrutiny increases surrounding biosimilars, particularly in the realm of pharmacovigilance (PV), it is imperative for pharmaceutical and biotechnology professionals to accurately navigate the complexities of traceability and product identification. This tutorial serves as a comprehensive guide on best practices and regulatory requirements concerning pharmacovigilance for biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products. By following these steps, professionals will be well-positioned to maintain compliance with the U.S. Food and Drug Administration (FDA), as well as the relevant authorities…

Understanding Signal Detection Complexities for Specialty and Rare Disease Products Pharmacovigilance is an essential aspect of drug safety, particularly for specialty and rare disease products, including biosimilars, vaccines, and advanced therapy medicinal products (ATMPs). This tutorial will help professionals in clinical operations, regulatory affairs, and medical affairs navigate the complexities involved in signal detection for these unique products. We will examine important factors such as adverse event following immunization (AEFI), traceability, and immunogenicity, providing a comprehensive overview tailored to the US, UK, and EU markets. 1. Introduction to Signal Detection in Pharmacovigilance Signal detection in pharmacovigilance refers to the process…

<!– PV Expectations for Advanced Therapy Medicinal Products ATMPs and Gene Therapies –> Understanding Pharmacovigilance Expectations for Advanced Therapy Medicinal Products (ATMPs) and Gene Therapies Introduction to Pharmacovigilance in the Context of ATMPs Pharmacovigilance (PV), defined by the World Health Organization as the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, is an essential part of ensuring drug safety post-approval. This is particularly crucial for Advanced Therapy Medicinal Products (ATMPs) and gene therapies, which often present unique challenges. Regulatory authorities, including the US FDA, UK Medicines and Healthcare products…

Designing PV Systems for Vaccines—Including AEFI and Special Reporting Rules Designing Pharmacovigilance Systems for Vaccines: A Guide for Professionals Introduction to Pharmacovigilance in Vaccines Pharmacovigilance (PV) encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. In the context of vaccines, effective pharmacovigilance is particularly vital due to their role in public health and the potential for widespread, long-term effects. This guide serves as a step-by-step tutorial for professionals involved in the design and operation of PV systems specifically for vaccines, particularly in relation to the reporting of Adverse…

Pharmacovigilance challenges and strategies for biosimilars in US and EU Understanding Pharmacovigilance Challenges and Strategies for Biosimilars in the US and EU Introduction to Pharmacovigilance in the Context of Biosimilars Pharmacovigilance is the science surrounding the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. This area of study becomes increasingly complex when considering biosimilars—biologics that are highly similar to already-approved reference products. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both impose strict regulations regarding pharmacovigilance for biosimilars to ensure safety and efficacy. Understanding the nuances of pharmacovigilance as it…